Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SFRVN

SAFC

Sf-RVN™ Insect Cell Line

Synonym(s):

Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

description

Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

Related Categories

General description

Sf-RVN(R)cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN™ Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN™ Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN™ Insect Cell Line. Combined, these two products form the Sf-RVN™ Platform.

Cell Line Origin

Sf-RVN™ is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN™ was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN™ cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN™ is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN ™ was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
EXACT-AIR is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PDSCL

Deleterious substance
Poisonous substance

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

SFRVN-CDMO-CL-IF:
SFRVN-CDMO-RA-AF:
SFRVN-C2:
SFRVN-RA-AF:
SFRVN-C3:
SFRVN-C1-AF:
SFRVN-C1-IF:
SFRVN-CDMO-RA-IF:
SFRVN-CDMO-CL-AF:
SFRVN-RA-IF:
SFRVN-1VL:4548173371931

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
2113192341
2113192341

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium

See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.

Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing

To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

Can AAV Continue to Deliver the Promise of Gene Therapy?

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

See All

Related Content

Viral Vector Upstream Platforms

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service